Upgrade to SI Premium - Free Trial

Quantum BioPharma (QNTM)

3.85 -0.15 (3.75%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26 *Est.)

Latest Headlines

Quantum BioPharma licensee Unbuzzd names new CEO, eyes stock listing September 24, 2026 8:01 AM - StreetInsider Form 6-K Quantum Biopharma Ltd. For: Sep 24 September 24, 2026 8:00 AM - SEC Filing Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO September 24, 2026 8:00 AM - Globe NewsWire Form 6-K Quantum Biopharma Ltd. For: Sep 17 September 17, 2026 3:13 PM - SEC Filing Form 6-K Quantum Biopharma Ltd. For: Sep 17 September 17, 2026 8:00 AM - SEC Filing Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target September 17, 2026 8:00 AM - Globe NewsWire Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target September 17, 2026 8:00 AM - StreetInsider Form 6-K Quantum Biopharma Ltd. For: Sep 15 September 15, 2026 8:00 AM - SEC Filing Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto September 15, 2026 8:00 AM - StreetInsider NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research September 14, 2026 8:30 AM - StreetInsider Quantum BioPharma gets FDA clearance for MS drug phase 2 trial September 11, 2026 8:31 AM - StreetInsider Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials September 11, 2026 8:30 AM - Globe NewsWire Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials September 11, 2026 8:30 AM - StreetInsider Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market September 10, 2026 8:30 AM - StreetInsider Quantum BioPharma gets FDA clearance for MS drug trial September 9, 2026 8:32 AM - StreetInsider Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment September 9, 2026 8:30 AM - StreetInsider A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach September 8, 2026 8:30 AM - StreetInsider Rodman & Renshaw Starts (QNTM) at Buy August 31, 2026 7:03 AM - StreetInsider Form 6-K Quantum Biopharma Ltd. For: Aug 14 August 14, 2026 7:00 AM - SEC Filing Quantum BioPharma gets FDA nod for Lucid-MS Phase 2 MS trial August 14, 2026 7:00 AM - StreetInsider Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial August 14, 2026 7:00 AM - StreetInsider Form 6-K Quantum Biopharma Ltd. For: Jun 30 August 13, 2026 4:08 PM - SEC Filing Form 6-K/A Quantum Biopharma Ltd. For: Aug 13 August 13, 2026 11:07 AM - SEC Filing Form 6-K Quantum Biopharma Ltd. For: Aug 10 August 10, 2026 7:00 AM - SEC Filing Quantum BioPharma gets FDA clearance for Lucid-MS phase 2 MS trial August 10, 2026 7:00 AM - StreetInsider Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: August 10, 2026 7:00 AM - StreetInsider Form SCHEDULE 13G Quantum Biopharma Ltd. Filed by: AdvisorShares Trust July 8, 2026 5:21 PM - SEC Filing Full Article List